AA
STML

Argent Advisors’s Stemline Therapeutics, Inc. STML Stock Holding History

Argent Advisors’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-500
Closed -$5K – 581
2019
Q4 		$5K Buy
+500
New +$4.96K ﹤0.01% 366

Other funds holding STML

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Argent Advisors's STML Position: Q1 2020 in Review

Argent Advisors sold out of Stemline Therapeutics, Inc. (STML) in Q1 2020, closing a stake of 500 shares — an estimated $5K sold.

Argent Advisors first reported a position in STML in Q4 2019 and held it in 1 quarter. The position peaked at $5K in Q4 2019. 94 funds tracked by Wall St. Rank hold STML as of Q1 2020.

  • Argent Advisors reported no remaining Stemline Therapeutics, Inc. position as of Q1 2020 after selling out during the quarter.
  • Argent Advisors sold 500 Stemline Therapeutics, Inc. shares in Q1 2020, an estimated $5K.
  • Argent Advisors first reported a position in Stemline Therapeutics, Inc. in Q4 2019 and held it in 1 quarter.
  • Argent Advisors's Stemline Therapeutics, Inc. position peaked at $5K in Q4 2019.
  • 94 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2020.

Based on Argent Advisors's 13F filing for Q1 2020, filed 23 Apr 2020.